Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for prostate cancer.

Lawrence Fong1, Eric J Small

  • 1Department of Medicine, University of California, San Francisco, CA 94143, USA.

Seminars in Oncology
|October 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025
Same author

A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025
Same author

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Nature genetics·2025
Same author

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

JNCI cancer spectrum·2025
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Novel immunotherapies, including tumor vaccines, show promise for advanced prostate cancer by targeting specific antigens like PSA, PAP, and PSMA. These approaches leverage T cell recognition for improved clinical efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Androgen deprivation therapy has been the standard for advanced prostate cancer for decades.
  • Emerging research focuses on novel immunotherapeutic strategies to complement existing treatments.

Purpose of the Study:

  • To explore the potential of immunotherapies for advanced prostate cancer.
  • To identify and utilize prostate-specific antigens as targets for novel treatment approaches.

Main Methods:

  • Identification of antigens recognized by T cells in prostate cancer.
  • Utilizing proteins like prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and prostate-specific membrane antigen (PSMA) as immunologic targets.
  • Leveraging advancements in cancer genomics and proteomics for target discovery.

Related Experiment Videos

Main Results:

  • Immunotherapy trials have demonstrated immunogenicity and clinical efficacy in prostate cancer.
  • Specific antigens (PSA, PAP, PSMA) have been successfully targeted for immunotherapy.

Conclusions:

  • Understanding immune recognition and antigen presentation is key to developing effective prostate cancer immunotherapies.
  • Future research will focus on building upon current findings to enhance immunotherapy efficacy.